Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Maridebart Cafraglutide

MARITIME-3-J

Amgen · Phase 3 · Active, not recruiting · Enrollment 279

NCT06987695

ArmPopulationDoseWeeksEstimandWeight change
Maridebart Cafraglutide High DoseObesity or overweightn/rn/rn/rn/r
Maridebart Cafraglutide Medium DoseObesity or overweightn/rn/rn/rn/r
Maridebart Cafraglutide Low DoseObesity or overweightn/rn/rn/rn/r
PlaceboObesity or overweightn/rn/rn/rn/r